Gene

TP53

tumor protein p53

Explore in graph →CI-GENE-00035913HGNC:11998 ENSG00000141510 NCBI 7157 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (408)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 301–350 of 408 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
TP53 R249S2
(functional)	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	submitted

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Adenocarcinoma (MSK, 2026) crc_msk_2026	Rectal Adenocarcinoma	Ssm	5,295	7,237	73.2%

Literature

Linked publications (58)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 58 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
· Blood · 2016 · PMID 26837699 · validated civic_curation pubmed
TP53 mutation and survival in chronic lymphocytic leukemia.
· J Clin Oncol · 2010 · PMID 20697090 · validated civic_curation pubmed
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
· Leukemia · 2015 · PMID 24943832 · validated civic_curation pubmed
Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
· J Clin Oncol · 2017 · PMID 28453411 · validated

TP53 R273C8
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID395 Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation. PMID 16489069 · Olivier et al., 2006 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID396 In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53. PMID 9569050 · Berns et al., 1998 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID7443 Several preclinical studies were testing how TP53-R273C variant induces over-expression of HER2 in various types of cancer cells. Through RT-qPCR, CC3A cells (harboring the TP53-R273C variant) were s… (full text at CIViC) PMID 29970031 · Román-Rosales et al., 2018 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Dominant Negative	3	accepted	EID10256 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Dominant Negative	3	submitted	EID10537 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant R273C originally identified in glioblastoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivat… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	submitted	EID9464 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic
Cisplatin + Etoposide + MitomycinCombination	Gastric CarcinomaALIAS	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID2292 A female patient taking part in a 25 patient gastric cancer trial was diagnosed at age 46, and received preoperative high dose chemotherapy (HDCT). Japanese Society for Gastric Cancer Response Score w… (full text at CIViC) PMID 14514923 · Bataille et al., 2003 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID4881 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic

TP53 R273H13
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID397 Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation. PMID 16489069 · Olivier et al., 2006 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID398 In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53. PMID 9569050 · Berns et al., 1998 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	4	submitted	EID7121 Plasmids harboring human TP53 with or without an R273H mutation were stably transfected into the murine fibroblast (10)3 and human osteosarcoma SAOS-2 cell lines, which lack endogenous p53 expression.… (full text at CIViC) PMID 8099841 · Dittmer et al., 1993 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	4	submitted	EID7433 Several preclinical studies were testing the gain of function mechanisms of the TP53-R273H variant. Under the presence of the wild-type TP53 and mutant TP53 genes, there is a dominant-negative (antimo… (full text at CIViC) PMID 14743206 · Willis et al., 2004 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Does Not Support Neomorphic	4	accepted	EID7530 The R273H mutation was used to create isogenic AML cell lines using MOLM13 and K526 lines. R273H/- cells showed resistance to chemotherapeutic agents and failure to induce p21, indicating disruption o… (full text at CIViC) PMID 31395785 · Boettcher et al., 2019 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Loss Of Function	3	submitted	EID7111 A reporter assay in FASAY yeast strain using the ADE2 gene under control of the p-21 or RGC p53 response elements was performed to assay p53 hotspot mutation R273H transcriptional activity, with colon… (full text at CIViC) PMID 27589690 · Billant et al., 2016 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Dominant Negative	3	submitted	EID7117 A reporter assay in FASAY yeast strain using the ADE2 gene under control of a p53 response element was performed, with colony color (white vs red) as readout for p53 transactivation activity, where wt… (full text at CIViC) PMID 27589690 · Billant et al., 2016 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Dominant Negative	3	submitted	EID10536 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant R273H originally identified in anaplastic astrocytoma. Should the mutant be dominant-negative (DN), TP53 will not bind and tr… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic
〃	—UNRESOLVED	Functional	D	Supports Loss Of Function	2	submitted	EID9465 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic
Doxorubicin + MethotrexateSubstitutes	Osteosarcoma	Predictive	D	Supports Resistance	3	accepted	EID7430 Several preclinical studies were testing drug resistance mechanisms of TP53-R273H variant. Saos-2 cells were transfected with TP53-R273H mutation and these cells were used in the study. Using a wester… (full text at CIViC) PMID 17363498 · Wong et al., 2007 · Open in CIViC	civic
MDM2 Inhibitor AMGMDS3	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	4	accepted	EID4882 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Tamoxifen	Malignant Breast Neoplasm	Predictive	C	Supports Resistance	—	submitted	EID2289 In a study 202 breast cancer patients undergoing tamoxifen treatment, a higher frequency of wildtype TP53 patients responded to treatment compared to those with mutations in TP53 (66% wild-type vs. 31… (full text at CIViC) PMID 10786679 · Berns et al., 2000 · Open in CIViC	civic
Temozolomide	GlioblastomaCURATED_BROADER	Predictive	D	Supports Resistance	3	submitted	EID7980 The glioblastoma U138 cell line possesses a TP53 R273H variant. This cell line initially exhibited resistance to temozolomide treatment, but a four-fold increase in chemosensitivity (IC50 127.79 ug/ml… (full text at CIViC) PMID 24248532 · Wang et al., 2014 · Open in CIViC	civic

TP53 Rearrangement2
(diagnostic)	Osteosarcoma	Diagnostic	B	Supports Positive	5	submitted	EID9247 Intron 1 rearrangements of TP53 were identified in 46 of 288 osteosarcoma cases (16%). No fusions were detected in 1090 other tumors screened. Fusions were associated with loss of TP53 expression. PMID 25762628 · Ribi et al., 2015 · Open in CIViC	civic
〃	Osteosarcoma	Diagnostic	B	Supports Positive	4	submitted	EID9248 TP53 fusions were identified in 10 of 25 osteosarcoma cases. The resulting inactivation of p53 was demonstrated by a deficiency of the radiation-induced DNA damage response. PMID 26672768 · Lorenz et al., 2016 · Open in CIViC	civic